HTSU.Y logo

Hisamitsu Pharmaceutical Co., Inc. Stock Price

OTCPK:HTSU.Y Community·US$425.2b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

HTSU.Y Share Price Performance

US$4.55
-2.25 (-33.04%)
US$4.55
-2.25 (-33.04%)
Price US$4.55

HTSU.Y Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet and fair value.

2 Risks
1 Reward

Hisamitsu Pharmaceutical Co., Inc. Key Details

JP¥163.0b

Revenue

JP¥66.9b

Cost of Revenue

JP¥96.1b

Gross Profit

JP¥77.0b

Other Expenses

JP¥19.2b

Earnings

Last Reported Earnings
Feb 28, 2026
Next Reporting Earnings
n/a
272.15
58.96%
11.75%
0.3%
View Full Analysis

About HTSU.Y

Founded
1847
Employees
2799
CEO
Kazuhide Nakatomi
WebsiteView website
www.global.hisamitsu

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to Asia, the United States, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan. As of February 19, 2026, Hisamitsu Pharmaceutical Co., Inc. operates as a subsidiary of Taiyo Kosan Co., Ltd.

Recent HTSU.Y News & Updates

No updates

Recent updates

No updates